Trospium Chloride Capsule, Extended Release
Product Images NDC 63629-8458

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 63629-8458). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Image 01)

Chemical structure diagram of Trospium Chloride, shown with its characteristic bicyclic and phenyl groups and chloride ion, corresponding to the active ingredient in Trospium Chloride ER 60 mg extended-release capsules by Bryant Ranch Prepack.*

FDA Label Image

Figure 1 (Image 02)

A line graph depicting plasma concentration (ng/mL) of Trospium Chloride Extended-Release Capsules 60 mg over 24 hours post-dose. The graph shows plasma concentration on the y-axis and hours post-dose on the x-axis, with data points and error bars indicating variability at each time point.*

FDA Label Image

Figure 2 (Image 03)

A line graph comparing the average (±SE) change over time between placebo (N=300) and Trospium Chloride Extended-Release Capsules (N=292). The y-axis represents average change, and the x-axis shows time points at 0, 1, 4, and 12 weeks. Data points include significance levels (p-values) indicating greater changes for Trospium Chloride ER at weeks 1, 4, and 12 compared to placebo.*

FDA Label Image

Figure 3 (Image 04)

A line graph comparing average change over time between placebo and Trospium Chloride Extended-Release Capsules groups. The y-axis represents average change with standard error, and the x-axis represents time points at 0, 1, 4, and 12 units. Data shows Trospium Chloride ER capsules produce greater average change than placebo, with p-values indicating statistical significance at several time points.*

FDA Label Image

Figure 4 (Image 05)

A line graph comparing the average (± standard error) change over time between placebo and Trospium Chloride Extended-Release Capsules groups. The x-axis represents time points (0, 1, 4, and 12), and the y-axis represents the average change. Trospium Chloride shows a greater decrease than placebo, with p-values indicating statistical significance at 4 and 12 units of time.*

FDA Label Image

Figure 5 (Image 06)

A line graph comparing average change (± standard error) over time between placebo and Trospium Chloride Extended-Release Capsules (60 mg) groups. Data points are shown at days 1, 4, and 12 with statistically significant differences (p<0.001) favoring Trospium Chloride at each time point. The y-axis represents average change, and the x-axis represents study days.*

FDA Label Image

Label (Lbl636298458)

Label for Trospium Chloride Extended-Release Capsules 60 mg by Bryant Ranch Prepack. The label includes the NDC 63629-8458-1, a barcode, dosage strength prominently in a black-bordered box, and the quantity of 30 capsules. Storage instructions and medication warnings are also shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.